Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company focused on discovering and developing medicines for a range of indications, reported second-quarter business highlights, spotlighting progress for ORX750, an oral selective orexin-2 receptor (OX2R) agonist in development for narcolepsy and other sleep disorders. “This is an exciting time for Centessa as we continue to execute across our…
If we want to be faithful followers of Jesus, we need to pay careful attention to our habits. Because we hand over much of our lives to our habits, much more than we probably realize. James Clear, author of Atomic Habits, describes a habit as “a behavior that has been repeated enough times to become…
ResMed PAP users are experiencing delays syncing data from their devices into myAir, AirView, and systems that integrate with AirView, an issue ResMed attributes to an over-the-air firmware update that introduced two new features and an improvement to the communication capabilities of the AirSense 11. According to a status update on the company’s website, the…
by Susan Adams and Penny HallasWhat is A Private Land? A Private Land is an art-based research and development project, supported by Arts Council Wales and undertaken in collaboration with community groups, with a central theme of the links between emotional and environmental health. Its funded timeframe is February – October 2023, but it is…
A new survey from the American Academy of Sleep Medicine (AASM) reveals that children are surrounded by disruptors impacting their ability to achieve sufficient, healthy sleep. Results show that parents blame video games (50%) and social media (44%) for negatively affecting the sleeping schedules of school-aged children and teens. That’s not the only thing disrupting…
Zevra Therapeutics Inc, a rare disease therapeutics company, provided second-quarter corporate updates, showcasing progress for KP1077, its drug candidate being investigated for the treatment of idiopathic hypersomnia and narcolepsy. During the quarter, Zebra continued the advancement of a phase 2 clinical trial evaluating KP1077 as an investigational treatment for idiopathic hypersomnia. The trial is actively…
Infants born to mothers with sleep-disordered breathing—snoring, apnea, and other breathing difficulties during sleep—are more likely to develop complications such as jaundice, low blood sugar, seizures, or death during the newborn period, suggests a study funded by the National Institutes of Health (NIH). The authors called for studies to determine if treating mid-pregnancy, sleep-disordered breathing…
August 14, 2023 • Institute Update Patricia A. Areán, Ph.D., has been selected as the new director of the National Institute of Mental Health’s (NIMH) Division of Services and Intervention Research (DSIR). She began her new role on August 13, 2023.DSIR supports research and training programs that aim to accelerate the translation of research findings…
Exor NV, a Netherlands-based diversified holding company behind luxury names like Ferrari and Christian Louboutin, has bought a 15% stake in Royal Philips, with an option to increase it to 20%. Exor’s investment, which grows its healthcare technology portfolio, fully supports Philips’ leadership, strategy, and value creation potential, according to a joint release from the…